The neuropeptide alpha-melanocyte stimulating hormone (a-MSH) plays an important role in immune privilege by its suppression of inflammation, and its induction of regulatory T cells. This finding led us to test the possibility that we can use a-MSH to suppress autoimmune diseases, and promote re-establishment of immune tolerance to autoantigens. To test this possibility, SJL mice with experimental autoimmune encephalomyelitis (EAE) were injected with a-MSH at the first signs of paralysis. The a-MSH-treated mice in comparison with untreated EAE mice had a profound diminishment in the severity and tempo of EAE. The spleen cells in a-MSH-treated EAE produced TGF-b in response to PLP-antigen stimulation in contrast to untreated mice spleen cells that produced IFN-c. When the a-MSH-treated EAE mice were reimmunized there was a delay of a week before the second episode of EAE. Although this delay maybe because of the induction of TGF-b-producing spleen cells by the a-MSH-treatment, it was not adequate to suppress IFN-c-production by PLP-antigen stimulated spleen cells from untreated mice, nor able to suppress the eventual second episode of EAE. Therefore, the injection of a-MSH at the onset of paralysis is extremely effective in diminishing the severity and tempo of EAE, and the subsequent induction of potential PLP-specific Treg cells suggests that an a-MSH therapy could be attempted as part of a therapeutic regiment to impose immunoregulation and immunosuppression on an autoimmune disease of the central nervous system.
Introduction
Certain tissue microenvironments called immune privileged uniquely regulate the immunogenic response by having a threshold to induce inflammation and immunity within their microenvironment that is higher than conventional tissues such as the skin. One of these immune privileged tissues is the eye (Streilein, 2003a) . The ocular microenvironment has evolutionarily adapted several molecular mechanisms to suppress the induction of inflammation and promote the activation of regulatory immunity. Our current understanding of the molecular mechanisms of ocular immune privilege has suggested the development of guided interventions and therapies with the molecules that mediate ocular immune privilege to (re)establish tolerance to self antigens (Streilein, 2003b; Taylor, 2007 ). An important mediator of immunoregulation and immunosuppression within the ocular microenvironment is the neuropeptide alpha-melanocyte stimulating hormone (a-MSH) (Taylor, 2003a) .
The neuropeptide a-MSH is a 13 amino acid long cleavage product of pro-opiomelanocortin hormone (Chakraborty et al., 1996; Lee et al., 1961) . The neuropeptide is expressed in various body tissues, fluids, and blood (Bohm et al., 2005; Holdeman et al., 1985; Taylor and Streilein, 1996; Taylor et al., 1992) . It has an important role in metabolic, pigmentary, and immune homeostasis (Bohm and
